Of the hundreds of agents being tested, inDemic.org selects the drugs most likely to have a significant impact on patients with COVID-19. The Watchlist is dynamic, with new drugs added and current drugs dropping off whenever new data prompts the changes. Selection for the Watchlist is based primarily on clinical trial data, but also on compelling mechanisms of action, signals of efficacy in compassionate use programs, and practical considerations such as manufacturing and distribution capacity to meet worldwide demand. Nominations for the Watchlist or other comments can be sent anytime to firstname.lastname@example.org.
Currently, only remdesivir and dexamethasone are widely used in treating COVID-19. Before the end of 2020, we predict that the first monoclonal antibodies (LY-CoV555) and antibody cocktails (REGN-COV2) will be authorized with an FDA EUA in select populations. In addition, we anticipate an FDA EUA for baricitinib and additional data on avdoralimab, opening the door to other JAK and complement inhibitors for treating COVID-19.
Here, we describe the next “catalysts” for each of the investigational therapies on “The COVID-19 Therapeutics Watchlist”, with attention to the potential im+*pact of each investigational therapy on the overall therapeutic toolkit against COVID-19.